New Zealand Society of Animal Production online archive

This paper is from the New Zealand Society for Animal Production online archive. NZSAP holds a regular annual conference in June or July each year for the presentation of technical and applied topics in animal production. NZSAP plays an important role as a forum fostering research in all areas of animal production including production systems, nutrition, meat science, animal welfare, wool science, animal breeding and genetics.

An invitation is extended to all those involved in the field of animal production to apply for membership of the New Zealand Society of Animal Production at our website www.nzsap.org.nz

The New Zealand Society of Animal Production in publishing the conference proceedings is engaged in disseminating information, not rendering professional advice or services. The views expressed herein do not necessarily represent the views of the New Zealand Society of Animal Production and the New Zealand Society of Animal Production expressly disclaims any form of liability with respect to anything done or omitted to be done in reliance upon the contents of these proceedings.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format

Under the following terms:

Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

NonCommercial — You may not use the material for commercial purposes.

NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.

http://creativecommons.org.nz/ licences/ licences-explained/
Control of reproductive success in rabbits using bromocriptine

Y.H. COTTAM, S.W. PETERSON AND S.N. McCUTCHEON

Department of Animal Science, Massey University, Palmerston North, New Zealand.

ABSTRACT

Feral rabbits impose a substantial environmental and economic cost in this country, causing pasture devastation over large areas of land, accelerating erosion and decreasing vegetation cover. Existing or potential methods of control have a high ethical cost, and there is a need to identify new methods of control. Manipulation of lactation, to enhance mortality and inhibit growth and development of the young, is a possible alternative strategy. Prolactin (PRL) is known to be important for establishment and maintenance of lactation in rabbits, and PRL secretion may be inhibited by administration of ergot alkaloids such as bromocriptine (CB154). These substances are orally active and so could potentially be used in baits. In order to determine whether CB154 could be used in baits, it is first necessary to establish the lowest effective dose. The objective of this study was therefore to examine the relationships between dose of CB154 (initially administered systemically) and the growth and survival of kits. Sixteen pregnant New Zealand White does were divided into four treatment groups receiving different doses (mg/kg live weight/d) of CB154 (“low” (L), 0.2; “medium” (M), 0.4; “high” (H), 0.8; and control (C), 0). From day 3 of lactation, does were injected once daily with CB154 or excipient. Treatment continued until day 14 or until the death of all the kits, whichever came first. There were significant treatment effects on the proportion of kit deaths on all measurement days. By day 17, kit mortalities were: C, 20%; L, 42%; M, 64%; H, 71%; (P<0.05). The weight gain of the surviving kits from day 3 to 8 did not differ significantly between treatment groups, but kit weight gain day from days 8 to 13 showed a significant treatment effect (P<0.01) (control, 83.7±11.4g; low, 18.7±11.4g; medium, 33.5±17.2g; high -0.8±14.9g). Results are discussed in relation to the possible use of bromocriptine as a bait to control reproductive success, and to the fact that these rabbits were much less sensitive to bromocriptine than previously published studies would suggest.

Keywords: rabbits; bromocriptine; CB154; prolactin.

INTRODUCTION

Feral rabbits impose a substantial environmental and economic cost on this country, the latter estimated at a minimum of $222 million dollars annually in control costs and lost production (RBAG 1996). Existing methods of feral rabbit control have a high ethical cost and problems of public non-acceptance. Manipulation of lactation, to enhance mortality and inhibit growth and development of young, is a possible alternative strategy.

For many years, prolactin (PRL) has been known to be important for the establishment and maintenance of lactation in rabbits (Cowie et al. 1969; Falconer and Fiddler 1970). With rabbit lactation being PRL-dependent, the inhibition of PRL secretion in the dam is expected to abolish lactation. PRL secretion may be inhibited by administration of ergot alkaloids such as bromocriptine (CB154) (Buys et al. 1995), which acts as a dopamine receptor agonist. Furthermore, these substances are orally active (Cingotti and Magnin 1986; Okkens et al. 1990) and so could potentially be used in baits. While CB154 has been used experimentally to inhibit lactation in the rabbit (Cowie et al. 1969; Taylor and Peaker 1975; Fortun et al. 1994) these studies focused on the biology of lactation rather than control of a noxious pest.

Ultimately, there may be potential to develop an oral dose of bromocriptine in a pellet acceptable to rabbits, which could be aerially broadcast over wide areas. This could be used to control feral rabbit populations, without the introduction of diseases or recourse to use of poisons. In order to determine whether CB154 could be used in baits, it is first necessary to establish the lowest effective dose. The objective of this study was therefore to examine the relationships between dose of systemically administered CB154 and the growth and survival of kits.

MATERIALS AND METHODS

Sixteen mixed-age pregnant New Zealand White does were housed in individual pens with ad libitum access to pellets and fresh water. Once they had kitted, does were randomly assigned to one of four treatment groups: control, ‘low’, ‘medium’ and ‘high’ dose of bromocriptine (Table 1). Live weights of the does on day 3 of lactation ranged from 4.0 to 5.2 kg, and litter size from 3 to 12.

Bromocriptine (2-bromo-α-ergo-cryptine; B-2134, Lot numbers 33H1393 and 83H0799, Sigma Chemical Company, U.S.A) was dissolved in 60% ethanol and 40% saline, at concentrations shown in Table 1. Does received once-daily subcutaneous injections commencing at 0900h on day 3 of lactation. The injection site, in the posterior neck region, was prepared by liberal application of 70% ethanol, and injections were performed using a 25G needle. Doses were calculated on the basis of an injection volume of 0.05 ml per kg live weight, and volumes ranged from 0.20 to 0.26 ml. Does were re-weighed after 7 days of treatment, and their injection volumes adjusted accord-
Bromocriptine solutions were made up weekly and refrigerated between injections.

**TABLE 1:** The doses and concentrations of bromocriptine.

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Dose (mg/kg/day)</th>
<th>Concentration of each stock solution (mg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0</td>
<td>0±0.0</td>
</tr>
<tr>
<td>Low</td>
<td>0.2</td>
<td>4</td>
</tr>
<tr>
<td>Medium</td>
<td>0.4</td>
<td>8</td>
</tr>
<tr>
<td>High</td>
<td>0.8</td>
<td>16</td>
</tr>
</tbody>
</table>

*Control animals were injected with 60% ethanol: 40% saline solution, at the same volume per kg body weight as treated animals.

**MEASUREMENTS**

Number of kits born in each litter (alive and dead) and date of kitting were recorded at birth. On the third day after kitting (day 1 of treatment), the live weight of each doe and total weight of kits in each litter were recorded. Does and kits were then weighed at kit ages 7, 8 or 9, and 12, 13 or 14 days of age. These groups will henceforth be referred to in terms of mean kit age, i.e., 8 and 13 days, respectively. The number of kits surviving per litter was noted daily at injection time. Injections continued until day 14 of lactation (i.e., day 11 of treatment), or until the death of all the kits in the litter, whichever came first. Until this time, the kits were solely dependent on the does’ milk.

Litter size (at day 1 of treatment) was assigned to two litter-size groups (2-7 and 8-12 kits), and treated as a class variable. Average weight gains of the kits between days 3 and 8, and days 8 and 13 were calculated and subjected to analysis of variance to test the effects of litter size, bromocriptine treatment and their interaction, and expressed as mean ± standard error. Doe weights were treated the same way, i.e., average weight gains were calculated and subjected to the same analyses as the kit weight gains.

The proportions of kit deaths per litter on days 8 and 13 were analysed using the SAS procedure for categorical data modelling (logit-transformation). Differences between group means were tested according to pre-planned comparisons using the Chi-Square statistic. Data were analysed using the computer statistical package SAS (1985).

**RESULTS**

There were significant treatment effects on day 8 (P<0.05) and day 13 (P<0.001) on the proportion of kit deaths (Table 2). On both of these days, the medium and high dose rates (0.4 and 0.8 mg/kg/day) showed greater mortality in the kits than the control or low (0.2mg/kg/day) dose rates. By day 17 (3 days after the end of treatment) there was a clear dose-relationship between treatment and kit mortality, with highest kit mortality in the medium and high dose groups.

**DISCUSSION**

The highest dose rate (0.8 mg/kg/day) used in this trial was chosen to give a range of doses greater than that reported previously in rabbits. Injecting rabbits with approximately 0.3 mg/kg/day starting on day 7 of lactation caused the death of all kits (Taylor and Peaker 1975), whereas a similar dose given later in lactation (from day
CB154 treatment of the does increased kit mortality, the upper limit on day 17 being achieved by the medium dose. Complete mortality did not occur, even at the highest dose. CB154 successfully retarded the weight gains of the surviving kits, with the upper limit of effect on weight gain being at the highest dose. Average weight gains of the control group kits over day 3 to day 8 (64g) and day 8 to day 13 (84g) of doe lactation compare favourably with those reported in kits of the same breed (52g and 20g, respectively) (Oetting et al. 1989), suggesting that the control animals grew “normally”.

The does in the control group lost weight (63g) between day 3 and day 8 of lactation. A weight loss in lactating does was also found by Fortun et al. (1993), who suggested that this could be due to mobilisation of maternal body protein and lipid reserves as increased intake alone was not sufficient to maintain lactation. In contrast, does in the treatment groups gained weight during this period, presumably because of reduced milk yield, as indicated by lower growth of kits. A maternal weight gain in treated does was also found by Fortun et al. (1994).

In summary, while CB154 treatment was effective in reducing kit growth and survival, consistent with reducing milk supply in their dams, our results suggest that does are more resistant to the effects of this drug than reported previously (Taylor and Peaker 1975). Given that a higher oral dose would be required to achieve the effects of systemic treatment at the doses used here, this raises doubts about the practicalities of using CB154 in baits.

REFERENCES


